For the second straight year, a young member of Wittenberg's alumni has cracked the annual Forbes 30 Under 30 list.
Congratulations to Lydia Kisley, who graduated from Wittenberg in 2010 with a bachelor's degree in chemistry and a minor in physics. The sixth annual Forbes 30 Under 30 list, announced in early January, highlights innovators who are under 30 years old and work in a variety of different industries, from media to manufacturing. Kisley, from Mentor, Ohio, was included in the healthcare category of the 2017 list.
Wittenberg's Derrick Braziel and William Thomas, class of 2009 and 2007 respectively, made last year's list in the entrepreneur category for their work and creation of MORTAR Cincinnati.
"I feel I was chosen to be part of the 30 Under 30 because I enjoy collaborating and working with other scientists, leading me to work on a lot of diverse projects, and also because I find it important to share my work through publications and presentations as often as possible," said Kisley, 28, who is a Beckman-Brown Interdisciplinary Postdoctoral Fellow at the University of Illinois at Urbana-Champaign. Kisley received her Ph.D. in chemistry in 2015 from Rice University in Houston, Texas.
"I was a little surprised that I was included on the healthcare list instead of the science list, as my work is very basic science compared to the impressive achievements of the other specialists on the list that includes surgeons and start-ups with clinical applications," she added. "But I hope that my research will reach and influence healthcare down the road. It's a great honor to be included on the list to affirm that all the late nights in the lab, working on the 20th draft of a publication, or getting stuck in an airport traveling from a conference are all worth it."
As a graduate student at Rice, one of the projects Kisley worked on included observing blood serum proteins combining with gold nanoparticles, which have been used in some cancer treatments. For more on this research, go to http://news.rice.edu/2014/01/21/better-protein-capture-a-boon-for-drug-manufacturers/#sthash.636QiNy0.dpuf